[HTML][HTML] Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic …
E Van Cutsem, MA Tempero, D Sigal… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
E Van Cutsem, MA Tempero, D Sigal, DY Oh, N Fazio, T Macarulla, E Hitre, P Hammel…
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.govRandomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus
Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage
MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive Search
in PMC Advanced Search User Guide Journal List J Clin Oncol PMC7499614 Other
Formats PDF (839K) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage
MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive Search
in PMC Advanced Search User Guide Journal List J Clin Oncol PMC7499614 Other
Formats PDF (839K) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Abstract
PURPOSE
To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA).
ncbi.nlm.nih.gov
